1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
1.3.1. Phase I - Secondary Research
1.3.2. Phase II - Primary Research
1.3.3. Phase III - Expert Panel Review
1.3.4. Assumptions
1.3.5. Approach Adopted
2. Executive Summary
2.1. Market Snapshot: Global Meningococcal Vaccines Market
2.3. Global Meningococcal Vaccines Market, By Type, 2025 (US$ Million)
2.4. Global Meningococcal Vaccines Market, By End-user, 2025 (US$ Million)
2.5. Global Meningococcal Vaccines Market, By Geography, 2025 (US$ Million)
2.6. Attractive Investment Proposition by Geography, 2025
3. Meningococcal Vaccines Market: Competitive Analysis
3.1. Market Positioning of Key Meningococcal Vaccines Market Vendors
3.2. Strategies Adopted by Meningococcal Vaccines Market Vendors
4. Meningococcal Vaccines Market: Macro Analysis & Market Dynamics
4.1. Introduction
4.2. Global Meningococcal Vaccines Market Value, 2024 - 2034, (US$ Million)
4.3. Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Key Challenges
4.3.4. Key Opportunities
4.4. Impact Analysis of Drivers and Restraints
4.5. Porter's Five Force Model
4.5.1. Supplier Power
4.5.2. Buyer Power
4.5.3. Threat Of Substitutes
4.5.4. Threat Of New Entrants
4.5.5. Competitive Rivalry
4.6. PESTEL Analysis
4.6.1. Political Landscape
4.6.2. Economic Landscape
4.6.3. Social Landscape
4.6.4. Technology Landscape
4.6.5. Environmental Landscape
4.6.6. Legal Landscape
5. Meningococcal Vaccines Market: By Type, 2024-2034, USD (Million)
5.1. Market Overview
5.2. Growth & Revenue Analysis: 2025 Versus 2034
5.3. Market Segmentation
5.3.1. Polysaccharide
5.3.1.1. Menomune
5.3.1.2. Mencevax
5.3.1.3. NmVac4
5.3.1.4. Others
5.3.2. Conjugate Vaccines
5.3.2.1. Menactra
5.3.2.2. Menveo
5.3.2.3. NeisVac-C
5.3.2.4. Nimenrix
5.3.2.5. Meningitec
5.3.2.6. Menjugate
5.3.2.7. MenAfriVac
5.3.2.8. NmVac4-DT
5.3.3. Combination Vaccines
5.3.3.1. MenHibrix
5.3.3.2. Menitorix
5.3.4. Men B Vaccines
5.3.4.1. Bexsero
5.3.4.2. Trumenba
6. Meningococcal Vaccines Market: By End-user, 2024-2034, USD (Million)
6.1. Market Overview
6.2. Growth & Revenue Analysis: 2025 Versus 2034
6.3. Market Segmentation
6.3.1. Retail Pharmacies
6.3.2. Hospital Pharmacies
6.3.3. Others (online pharmacies, drug stores)
7. North America Meningococcal Vaccines Market, 2024-2034, USD (Million)
7.1. Market Overview
7.2. Meningococcal Vaccines Market: By Type, 2024-2034, USD (Million)
7.3. Meningococcal Vaccines Market: By End-user, 2024-2034, USD (Million)
7.4. Meningococcal Vaccines Market: By Region, 2024-2034, USD (Million)
7.4.1.North America
7.4.1.1. U.S.
7.4.1.1.1. Meningococcal Vaccines Market: By Type, 2024-2034, USD (Million)
7.4.1.1.2. Meningococcal Vaccines Market: By End-user, 2024-2034, USD (Million)
7.4.1.2. Canada
7.4.1.2.1. Meningococcal Vaccines Market: By Type, 2024-2034, USD (Million)
7.4.1.2.2. Meningococcal Vaccines Market: By End-user, 2024-2034, USD (Million)
7.4.1.3. Rest of North America
7.4.1.3.1. Meningococcal Vaccines Market: By Type, 2024-2034, USD (Million)
7.4.1.3.2. Meningococcal Vaccines Market: By End-user, 2024-2034, USD (Million)
8. UK and European Union Meningococcal Vaccines Market, 2024-2034, USD (Million)
8.1. Market Overview
8.2. Meningococcal Vaccines Market: By Type, 2024-2034, USD (Million)
8.3. Meningococcal Vaccines Market: By End-user, 2024-2034, USD (Million)
8.4. Meningococcal Vaccines Market: By Region, 2024-2034, USD (Million)
8.4.1.UK and European Union
8.4.1.1. UK
8.4.1.1.1. Meningococcal Vaccines Market: By Type, 2024-2034, USD (Million)
8.4.1.1.2. Meningococcal Vaccines Market: By End-user, 2024-2034, USD (Million)
8.4.1.2. Germany
8.4.1.2.1. Meningococcal Vaccines Market: By Type, 2024-2034, USD (Million)
8.4.1.2.2. Meningococcal Vaccines Market: By End-user, 2024-2034, USD (Million)
8.4.1.3. Spain
8.4.1.3.1. Meningococcal Vaccines Market: By Type, 2024-2034, USD (Million)
8.4.1.3.2. Meningococcal Vaccines Market: By End-user, 2024-2034, USD (Million)
8.4.1.4. Italy
8.4.1.4.1. Meningococcal Vaccines Market: By Type, 2024-2034, USD (Million)
8.4.1.4.2. Meningococcal Vaccines Market: By End-user, 2024-2034, USD (Million)
8.4.1.5. France
8.4.1.5.1. Meningococcal Vaccines Market: By Type, 2024-2034, USD (Million)
8.4.1.5.2. Meningococcal Vaccines Market: By End-user, 2024-2034, USD (Million)
8.4.1.6. Rest of Europe
8.4.1.6.1. Meningococcal Vaccines Market: By Type, 2024-2034, USD (Million)
8.4.1.6.2. Meningococcal Vaccines Market: By End-user, 2024-2034, USD (Million)
9. Asia Pacific Meningococcal Vaccines Market, 2024-2034, USD (Million)
9.1. Market Overview
9.2. Meningococcal Vaccines Market: By Type, 2024-2034, USD (Million)
9.3. Meningococcal Vaccines Market: By End-user, 2024-2034, USD (Million)
9.4. Meningococcal Vaccines Market: By Region, 2024-2034, USD (Million)
9.4.1.Asia Pacific
9.4.1.1. China
9.4.1.1.1. Meningococcal Vaccines Market: By Type, 2024-2034, USD (Million)
9.4.1.1.2. Meningococcal Vaccines Market: By End-user, 2024-2034, USD (Million)
9.4.1.2. Japan
9.4.1.2.1. Meningococcal Vaccines Market: By Type, 2024-2034, USD (Million)
9.4.1.2.2. Meningococcal Vaccines Market: By End-user, 2024-2034, USD (Million)
9.4.1.3. India
9.4.1.3.1. Meningococcal Vaccines Market: By Type, 2024-2034, USD (Million)
9.4.1.3.2. Meningococcal Vaccines Market: By End-user, 2024-2034, USD (Million)
9.4.1.4. Australia
9.4.1.4.1. Meningococcal Vaccines Market: By Type, 2024-2034, USD (Million)
9.4.1.4.2. Meningococcal Vaccines Market: By End-user, 2024-2034, USD (Million)
9.4.1.5. South Korea
9.4.1.5.1. Meningococcal Vaccines Market: By Type, 2024-2034, USD (Million)
9.4.1.5.2. Meningococcal Vaccines Market: By End-user, 2024-2034, USD (Million)
9.4.1.6. Rest of Asia Pacific
9.4.1.6.1. Meningococcal Vaccines Market: By Type, 2024-2034, USD (Million)
9.4.1.6.2. Meningococcal Vaccines Market: By End-user, 2024-2034, USD (Million)
10. Latin America Meningococcal Vaccines Market, 2024-2034, USD (Million)
10.1. Market Overview
10.2. Meningococcal Vaccines Market: By Type, 2024-2034, USD (Million)
10.3. Meningococcal Vaccines Market: By End-user, 2024-2034, USD (Million)
10.4. Meningococcal Vaccines Market: By Region, 2024-2034, USD (Million)
10.4.1.Latin America
10.4.1.1. Brazil
10.4.1.1.1. Meningococcal Vaccines Market: By Type, 2024-2034, USD (Million)
10.4.1.1.2. Meningococcal Vaccines Market: By End-user, 2024-2034, USD (Million)
10.4.1.2. Mexico
10.4.1.2.1. Meningococcal Vaccines Market: By Type, 2024-2034, USD (Million)
10.4.1.2.2. Meningococcal Vaccines Market: By End-user, 2024-2034, USD (Million)
10.4.1.3. Rest of Latin America
10.4.1.3.1. Meningococcal Vaccines Market: By Type, 2024-2034, USD (Million)
10.4.1.3.2. Meningococcal Vaccines Market: By End-user, 2024-2034, USD (Million)
11. Middle East and Africa Meningococcal Vaccines Market, 2024-2034, USD (Million)
11.1. Market Overview
11.2. Meningococcal Vaccines Market: By Type, 2024-2034, USD (Million)
11.3. Meningococcal Vaccines Market: By End-user, 2024-2034, USD (Million)
11.4. Meningococcal Vaccines Market: By Region, 2024-2034, USD (Million)
11.4.1.Middle East and Africa
11.4.1.1. GCC
11.4.1.1.1. Meningococcal Vaccines Market: By Type, 2024-2034, USD (Million)
11.4.1.1.2. Meningococcal Vaccines Market: By End-user, 2024-2034, USD (Million)
11.4.1.2. Africa
11.4.1.2.1. Meningococcal Vaccines Market: By Type, 2024-2034, USD (Million)
11.4.1.2.2. Meningococcal Vaccines Market: By End-user, 2024-2034, USD (Million)
11.4.1.3. Rest of Middle East and Africa
11.4.1.3.1. Meningococcal Vaccines Market: By Type, 2024-2034, USD (Million)
11.4.1.3.2. Meningococcal Vaccines Market: By End-user, 2024-2034, USD (Million)
12. Company Profile
12.1. Sanofi SA (Company Overview, Financial Performance, Product Portfolio, Strategic Initiatives)
12.2. Novartis International
12.3. GlaxoSmithKline plc
12.4. Pfizer Inc.
12.5. Nuron Biotech
12.6. JN-International Medical Corporation
12.7. Serum Institute of India Ltd
12.8. Baxter International
12.9. Biomed Pvt. Ltd
